Loading...
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
In the present study, we evaluated the efficacy and safety of rituximab in combination with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with classical Hodgkin lymphoma (cHL). In this phase 2 study, patients with chemotherapy-naive, advanced-stage cHL were treate...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society of Hematology
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3359733/ https://ncbi.nlm.nih.gov/pubmed/22371887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-01-405456 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|